Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Astellas Pharma Inc. (ALPMY.OB) Astellas Pharma has sought FDA approval to add positive 2-year data to the label of IZERVAY injection for the treatment of Geographic Atrophy, and a decision is ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

The company stressed that the regulator has no issues with the safety and efficacy data submitted for the label update ... the clinical profile of Izervay, the only FDA-approved GA treatment ...

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration (AMD). Izervay can cause side effects that range from mild to serious. Examples ...

That was followed shortly after by the FDA approval of Astellas' C5 inhibitor Izervay (avacincaptad pegol), although, a subsequent attempt by the company to broaden its label was turned down.

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...